A Randomized Trial to Evaluate Sequential vs Simultaneous Patching
Launched by JAEB CENTER FOR HEALTH RESEARCH · May 5, 2020
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the best way to treat amblyopia, often known as "lazy eye," in children aged 3 to just under 13 years. Specifically, it will compare two treatment methods: one where children wear glasses first and only use a patch if needed later, and another where they wear glasses and a patch at the same time. The goal is to see if both approaches lead to similar improvements in vision.
To be part of this study, children need to have amblyopia linked to issues like differences in eye strength (anisometropia) or misaligned eyes (strabismus). They should not have received any prior treatment for amblyopia. Participants will wear glasses prescribed for their specific needs and may be asked to wear a patch over the stronger eye to help improve vision in the weaker one. Parents should know that the study is ongoing and that their child will be randomly assigned to one of the two treatment methods, with the aim of making vision better.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Age 3 to \<13 years at the time of randomization
- • 2. Amblyopia associated with anisometropia, strabismus, or both
- o Criteria for strabismic amblyopia: At least one of the following must be met:
- • Presence of a heterotropia on examination at distance or near fixation (with or without optical correction)
- • Documented history of strabismus which is no longer present (which in the judgment of the investigator could have caused amblyopia)
- * Criteria for anisometropia: At least one of the following criteria must be met:
- • 1.00 D difference between eyes in spherical equivalent (SE)
- • 1.50 D difference in astigmatism between corresponding meridians in the two eyes
- * Criteria for combined-mechanism amblyopia: Both of the following criteria must be met:
- • Criteria for strabismus are met (see above)
- • 1.00 D difference between eyes in spherical equivalent OR ≥1.50 D difference in astigmatism between corresponding meridians in the two eyes
- • 3. No previous treatment for amblyopia, including no more than 24 hours of spectacle wear.
- 4. Investigator planning to initiate spectacle correction of refractive error meeting the following criteria based on a cycloplegic refraction that has been performed within 30 days:
- • 1. Full correction of anisometropia
- • 2. Full correction of astigmatism with the same axis found by the cycloplegic refraction
- • 3. Full correction of any myopia
- • 4. Hyperopia must not be under corrected by more than 1.50 D, and reduction in plus sphere must be symmetric in the two eyes.
- 5. At enrollment, single VA measured in each eye assessed in trial frames with the spectacle correction the investigator plans to prescribe, using the investigator's routine method as follows:
- • VA in the amblyopic eye 20/40 to 20/200 inclusive.
- • Age-normal VA in the fellow eye:40,41
- • 3 years: 0.4 logMAR (20/50) or better
- • 4 years: 0.3 logMAR (20/40) or better
- • 5-6 years: 0.2 logMAR (20/32) or better
- • 7-12 years: 0.12 logMAR (78 letters) or better
- • Interocular difference ≥ 3 logMAR lines (0.3 logMAR) or ≥ 15 letters o When participants return for the Spectacle Baseline / Randomization Visit with their new spectacles, they will need to meet the same criteria as above using the ATS-HOTV or E-ETDRS protocol after wearing the new spectacles for at least 10 minutes (based upon the mean of a test and retest of VA in those new spectacles).
- • 6. Investigator is willing to prescribe spectacle wear followed sequentially by patching or simultaneous spectacles and patching treatment per protocol.
- • 7. Parent understands the protocol and is willing to accept randomization.
- • 8. Parent has phone (or access to phone) and is willing to be contacted by Jaeb Center staff or other study staff.
- • 9. Relocation outside of area of an active PEDIG site for this study within the next 56 weeks is not anticipated.
- Exclusion Criteria:
- • 1. Myopia greater than -6.00 D spherical equivalent in either eye.
- • 2. Previous intraocular or refractive surgery.
- • 3. Planned strabismus surgery in the next 56 weeks.
- • 4. Any previous treatment for amblyopia (patching, atropine, Bangerter filter, vision therapy, or binocular treatment).
- • 5. Previous spectacle or contact lens wear for more than 24 hours.
- • 6. Parent and participant willing to forego option of contact lens wear for the duration of the study.
- • 7. Ocular co-morbidity that may reduce VA determined by an ocular examination performed within the past 7 months (Note: nystagmus per se does not exclude the participant if the above VA criteria are met).
- • 8. Severe developmental delay that would interfere with treatment or evaluation (in the opinion of the investigator). Participants with mild speech delay or reading and/or learning disabilities or attention deficit hyperactivity disorder (ADHD) are not excluded.
- • 9. Known allergy to adhesive patches.
- • 10. Known allergy to silicone.
About Jaeb Center For Health Research
The Jaeb Center for Health Research is a leading nonprofit organization dedicated to advancing medical research through innovative clinical trials and data analysis. With a strong emphasis on improving patient outcomes, the Center collaborates with healthcare professionals and institutions to conduct rigorous studies across various therapeutic areas, particularly in ophthalmology and diabetes. By leveraging cutting-edge methodologies and a commitment to ethical research practices, the Jaeb Center strives to enhance the understanding of disease mechanisms and develop effective treatment options, ultimately contributing to the improvement of public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Rochester, Minnesota, United States
Baltimore, Maryland, United States
Houston, Texas, United States
Birmingham, Alabama, United States
Palo Alto, California, United States
Boston, Massachusetts, United States
Jacksonville, Florida, United States
Sacramento, California, United States
Kansas City, Missouri, United States
Durham, North Carolina, United States
Rochester, Minnesota, United States
Chicago, Illinois, United States
Lubbock, Texas, United States
Tucson, Arizona, United States
Philadelphia, Pennsylvania, United States
Oklahoma City, Oklahoma, United States
Portland, Oregon, United States
Cincinnati, Ohio, United States
Baltimore, Maryland, United States
Akron, Ohio, United States
Laramie, Wyoming, United States
Bloomington, Indiana, United States
Columbus, Ohio, United States
Tucson, Arizona, United States
Loma Linda, California, United States
New York, New York, United States
Erie, Pennsylvania, United States
Memphis, Tennessee, United States
Birmingham, Alabama, United States
Omaha, Nebraska, United States
West Des Moines, Iowa, United States
Chapel Hill, North Carolina, United States
Spokane, Washington, United States
Salt Lake City, Utah, United States
New York, New York, United States
Seattle, Washington, United States
Fullerton, California, United States
Norfolk, Virginia, United States
San Antonio, Texas, United States
Lancaster, Pennsylvania, United States
Glendale, Arizona, United States
Pomona, California, United States
San Francisco, California, United States
Fort Lauderdale, Florida, United States
Boise, Idaho, United States
Downers Grove, Illinois, United States
Grand Rapids, Michigan, United States
Grand Rapids, Michigan, United States
Saint Louis, Missouri, United States
Philadelphia, Pennsylvania, United States
Chicago Ridge, Illinois, United States
Lisle, Illinois, United States
Saint Louis, Missouri, United States
Columbia, South Carolina, United States
Boston, Massachusetts, United States
Nashville, Tennessee, United States
San Antonio, Texas, United States
Indianapolis, Indiana, United States
Milford, Connecticut, United States
Sartell, Minnesota, United States
Buffalo, New York, United States
Albany, Oregon, United States
Fort Worth, Texas, United States
San Antonio, Texas, United States
Irvine, California, United States
Phoenix, Arizona, United States
Berkeley, California, United States
Grand Rapids, Michigan, United States
Los Angeles, California, United States
Tampa, Florida, United States
New York, New York, United States
Patients applied
Trial Officials
Vivian Manh
Study Chair
Seattle Children's Hospital, University of Washington
Michael Gray
Study Chair
Children's Hospital Medical Center, Cincinnati
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials